ANI Pharmaceuticals intends to price public offering of common stock

Bookrunners Oppenheimer and Roth Capital Partners to assist with sale

By Devika Patel

Knoxville, Tenn., March 4 - ANI Pharmaceuticals, Inc. will price a public offering of common stock with a 30-day 15% greenshoe, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Oppenheimer & Co. and Roth Capital Partners are the joint bookrunning managers.

Proceeds will be used to research, develop, commercialize and expand drug products, to acquire businesses and technologies and for working capital and other general corporate purposes.

The pharmaceutical company is based in Baudette, Minn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.